MARKET

EYPT

EYPT

EyePoint
NASDAQ
18.05
-0.22
-1.20%
Opening 10:08 01/02 EST
OPEN
18.36
PREV CLOSE
18.27
HIGH
18.50
LOW
17.80
VOLUME
78.47K
TURNOVER
--
52 WEEK HIGH
19.11
52 WEEK LOW
3.910
MARKET CAP
1.49B
P/E (TTM)
-6.0376
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at EYPT last week (1222-1226)?
Weekly Report · 12/29/2025 09:12
3 Biotech Stocks Wall Street Analysts Are Bullish on for 2026
NASDAQ · 12/22/2025 13:10
Weekly Report: what happened at EYPT last week (1215-1219)?
Weekly Report · 12/22/2025 09:12
The 2 Riskiest Stocks Investors Are Betting On With Over 300% Upside
Barchart · 12/20/2025 11:00
EyePoint Inc. to Present at J.P. Morgan Healthcare Conference
Reuters · 12/17/2025 12:00
EyePoint Grants Stock Options to New Employees as Inducement Awards
Reuters · 12/16/2025 12:00
EYEPOINT REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 12/16/2025 12:00
Buy Recommendation for EyePoint Pharmaceuticals: Strong Clinical Positioning and Market Potential of Duravyu in Wet AMD
TipRanks · 12/15/2025 18:35
More
About EYPT
EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. Additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.

Webull offers EyePoint Inc stock information, including NASDAQ: EYPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EYPT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EYPT stock methods without spending real money on the virtual paper trading platform.